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The farnesoid X receptor (FXR) belonging to the metabolic subfamily of nuclear receptors is a ligand-
induced transcriptional activator. Its central function is the physiological maintenance of bile acid
homeostasis including the regulation of glucose and lipid metabolism. Accessible structural information
about its ligand-binding domain renders FXR an attractive target for in silico approaches. Integrated to
natural product research these computational tools assist to ﬁnd novel bioactive compounds showing
beneﬁcial effects in prevention and treatment of, for example, the metabolic syndrome, dyslipidemia,
atherosclerosis, and type 2 diabetes. Virtual screening experiments of our in-house Chinese Herbal
Medicine database with structure-based pharmacophore models, previously generated and validated,
revealed mainly lanostane-type triterpenes of the TCM fungus Ganoderma lucidum Karst. as putative
FXR ligands. To verify the prediction of the in silico approach, two Ganoderma fruit body extracts and
compounds isolated thereof were pharmacologically investigated. Pronounced FXR-inducing effects were
observed for the extracts at a concentration of 100 lg/mL. Intriguingly, ﬁve lanostanes out of 25 second-
ary metabolites from G. lucidum, that is, ergosterol peroxide (2), lucidumol A (11), ganoderic acid TR (12),
ganodermanontriol (13), and ganoderiol F (14), dose-dependently induced FXR in the low micromolar
range in a reporter gene assay. To rationalize the binding interactions, additional pharmacophore proﬁl-
ing and molecular docking studies were performed, which allowed establishing a ﬁrst structure–activity
relationship of the investigated triterpenes.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction FXR, like other nuclear receptors, comprises a variable modularFarnesoid X receptor (FXR; NR1H4), a ligand-induced transcrip-
tional activator is a member of the nuclear hormone receptor
superfamily.1 It is expressed in liver, intestine, kidney, adrenal
glands, and also in the vasculature where FXR might play a role
in the pathogenesis of cardiovascular diseases.1,2, 3D structural database of
d Eagle’s Medium; FBS, fetal
man embryonic kidney-293;
or; SHP-1, small heterodimer
x: +43 512 507 2939.
llinger).
Y-NC-ND license.region, a conserved DNA binding domain (DBD) and a ligand bind-
ing domain (LBD).3 It acts as monomer (e.g., stimulating the
expression of the main insulin-responsive glucose transporter
GLUT4), as homodimer, or preferentially with its partner the nucle-
ar receptor 9-cis-retionic acid receptor (RXR), forming an FXR/RXR-
heterodimer.3,4 Upon ligand binding, the receptor connects to DNA
which results either in an up-regulation or repression of gene tran-
scription.3 The resulting mechanisms are inﬂuenced by the agonist
or antagonist character of the respective ligand.3
In 1999, FXR has been found to be a key target for bile acids
(BAs).5–7 Representing endogenous signaling molecules, BAs nega-
tively regulate their own synthesis by repressing the transcription
of cholesterol 7a-hydroxylase (CYP7A1), a cytochrome P450
enzyme essential for the synthesis of cholesterol. This mechanism
6780 U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791involves the small heterodimer partner 1 (SHP-1), a nuclear recep-
tor without DBD.8,9
Among others, genes encoding the intestinal bile acid-binding
protein (IBABP) and the bile salt export pump (BSEP) are also reg-
ulated via FXR activation.5,10,11 The involved mechanisms are
important for BA secretion and transportation.
Besides cholic acid (CA), deoxycholic acid (DCA) and lithocholic
acid (LCA), the primary BA chenodeoxycholic acid (CDCA) repre-
sents the most potent endogenous FXR ligand with EC50 values
between 10 and 50 lM (Chart 1).3,5–7 For a pharmacological char-
acterization and evaluation of the drugability of FXR, several syn-
thetic ligands have been developed. These can be categorized in
steroids (Chart 1), like, for example, 6-ethylchenodeoxycholic acid
(6-ECDCA; INT-747),12 and non steroids (Chart 2), like, for example,
GW4064,13 AGN29,14 and AGN31.14
For the identiﬁcation of steroidal FXR ligands, derivatives of BAs
have been developed to explore their structure–activity relation-
ships. The thereby discovered most potent orally administered ste-
roidal FXR agonist 6-ECDCA (INT-747)12 (Chart 1) could already
enter clinical studies for type 2 diabetes mellitus with presumed
nonalcoholic fatty liver disease (NAFLD) and primary biliary cirrho-
sis (PBC).15 Further clinical trials include the steroidal FXR ligands
CDCA, and ursodeoxycholic acid (UDCA) (Chart 1).15
Among non-steroidal FXR agonists, especially GW4064 (Chart
2) has been studied intensively. Using this potent FXR agonist as
lead structure, efforts to overcome shortcomings, that is, limited
oral exposure, short terminal half-life, potential toxicity of the
stilbene moiety, and UV light instability have been undertaken
by various research groups. Analogues of GW4064 were synthe-
sized by replacing the stilbene by naphthalene or benzothiophene
rings which however in most cases did not result in improved FXR
potency.16,17 Current approaches led to the generation of moreOH
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Chart 1. Examples of chemical strueffective GW4064 analogues by replacing the stilbene double bond
by an oxymethylene or amino-methylene linker connecting a ter-
minal benzoic acid with a substituted heteroaryl in the middle ring
position.18
Aside from mentioned GW4064 analogues, high-through-
put screening campaigns revealed benzimidazole derivatives
and azepino(4,5-b)indole derivatives as new classes of FXR
agonists.19
WAY-362450 (Chart 2), a representative of the latter group, was
investigated in the course of clinical trials in healthy subjects to
validate the safety, tolerability, and pharmacokinetics of this orally
administered FXR agonist.20
In recent publications the relevance of FXR as BA activated
receptor was illuminated with regard to the treatment of athero-
sclerosis and its counter-regulatory role in immunity and inﬂam-
mation.21,22 Beneﬁcial effects of FXR agonists are reported for the
modulation of lipids23 and glucose as well as hepatobiliary and
gastrointestinal diseases.24
On the one hand FXR holds a regulative function in many
endogenous pathways and on the other hand the features of its
active site are well-characterized.25,26 These essential facts contrib-
ute to the attractiveness of this nuclear receptor as novel drugable
target to ﬁnd innovative agents showing favorable effects in the
prevention and treatment of, for example, the metabolic syndrome,
dyslipidemia, atherosclerosis, and type 2 diabetes.25,26
Especially in recent years natural products regulating nuclear
receptors have been found to play an important role as promising
candidates in drug development.27 Concerning the nuclear recep-
tor FXR, the most investigated ones are the stereoisomeres E- and
Z-guggulsterone (Chart 3), the bioactive constituents of the stem
bark resin of Commiphora mukul (Burseraceae), which is used in
Ayurvedic medicine for the treatment of lipid disorders andOHHO
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Chart 3. Chemical structures of stereoisomeres Z- and E-guggulsterone, fexaramine (y-shaped synthetic FXR agonist used for co-crystallization with human FXR as reported
in the PDB entry 1osh), and MFA-1 (synthetic FXR agonist used for co-crystallization with human FXR as reported in the PDB entry 3bej).
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Chart 2. Examples of chemical structures of non-steroidal FXR ligands.
U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791 6781obesity.28 The pregnane derivatives E- and Z-guggulsterone, as ob-
served in a mouse model, act as FXR antagonists, which regulate
the expression of a subset of targetgenes.29 Efforts to discover
the mode of action of these cholesterol-lowering compounds re-
vealed an FXR-antagonism by suppressing the expression of BSEP
and upregulating CYP7A1. However, this mechanism is combined
with the ability to dominantly enhance the transactivation of BSEP,
thus indirectly leading to an FXR-agonistic effect.30
Several studies report also an interaction of E- and Z-gugguls-
terone with additional nuclear receptors such as, for example,
the androgen receptor (AR), estrogen receptor (ERa), glucocorticos-
teroid receptor (GR), mineralcorticoid receptor (MR), progesterone
receptor (PR), and the pregnane X receptor (PXR).31,32 Furthermore,
guggulsterone inhibits iNOS and COX-2 gene expressions, a mech-
anism which is suggested to involve the inhibition of NF-jB
activation.33An FXR-antagonism is postulated for scalarane-based sester-
terpenes isolated from a marine sponge of the genus Spongia.34
Xanthohumol, a prenylated chalcone, derived from Humulus lupu-
lus (Cannabaceae) and extracts of the two traditional Chinese herbs
Salvia miltiorrhiza (Lamiaceae) and Panax notoginseng (Araliaceae)
are examples demonstrating FXR-inducing activity.35–37
The fruiting body of Ganoderma lucidum Karst. (reishi in Japan or
língzhı¯ in China), of the Ganodermataceae family, has been widely
used in Asian traditional medicines for more than 2000 years. Many
studies about the constituents of this medicinal mushroom have
indicated antitumor, immunostimulating, anti-diabetic, anti-inﬂam-
matory, antiviral, antibacterial, antihypertensive, and hypolipidem-
ic activities.38 The pronounced pharmacological effects are mainly
caused by triterpenes and polysaccharides. Over 200 triterpenes,
mostly deﬁned by an unsaturated lanostane scaffold, have been iso-
lated from G. lucidum and the genus Ganoderma.39 Due to the broad
6782 U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791spectrum of pharmacological effects related to G. lucidum and the
vast number of involved constituents, an exactmechanism of action
has only been assigned to a few compounds.
In this study we demonstrate the application of in silico tools
for the identiﬁcation of natural products, namely Ganoderma
lanostane-type triterpenes as potent FXR agonists. These results
might be in close relation to the known hypolipidemic and anti-
inﬂammatory effects of the investigated medicinal fungus.
2. Results and discussion
For the identiﬁcation of FXR ligands from natural sources we se-
lected a virtual screening approach. Based on the protein data bank
(PDB)40 crystal structure entry 1osh41 comprising a y-shaped
hydrophobic ligand (Chart 3) within the binding site of the nuclear
receptor FXR, a structure-based pharmacophore model (1osh-1)
was created and validated in part I of this study.42 The generated
model consists of ﬁve hydrophobic features, one hydrogen bond
acceptor with His294, and 27 exclusion volume spheres (Fig. 1).
Virtual screening of our in-house Chinese Herbal Medicine
(CHM) database,43 comprising 10,216 compounds, with the 1osh-
1 model resulted in a list of 572 virtual hits (VHs) ranked according
to their computationally derived best ﬁt values. The analysis of the
VHs comprising various compound classes involved several param-
eters, for example, already known FXR-related effects, commercial
availability of the natural starting material or the pure compound,
and accessibility of the selected VHs from natural sources.
Considering these aspects a set of representatives has been
selected for pharmacological evaluation of the predicted FXR-
inducing potential taking into account diverse structure classes
such as triterpenes, ﬂavonoids, furanocoumarins, quinolone deriv-
atives, carotenoids, and fatty acid derivatives. The selected VHs
were found to be constituents of the fruit bodies of G. lucidum
(GL), Ginkgo biloba (GB) leaves, Vitex agnus-castus (VAC) fruits, Ruta
graveolens (RG) roots and leaves, Capsicum annum (CA) fruits, or
Panax ginseng (PG) roots (Table 1).
To validate the in silico predictions extracts of different polarity
(D = DCM; M = MeOH), an enriched ethyl acetate (EA) fraction, and
available pure compounds (artemisetin, dihydrocapsaicin, and
rutamarin) were screened for their FXR inducing potential in a
reporter gene assay. The pharmacological evaluation of these
substances was performed in HEK293 cells transiently transfectedFigure 1. 1osh-1 Pharmacophore model comprising ﬁve hydrophobic features, one
hydrogen bond acceptor with His294, and 27 exclusion volume spheres (ligand:
fexaramine).with the FXR reporter assay system comprising the ECRE-Luc re-
porter plasmid containing quintuple RXR:FXR binding site and
the respective expression plasmids for full length murine FXR
and RXRa. Correction for transfection efﬁciency of each sample
was ensured by normalization of the ﬁreﬂy luciferase values to
renilla luciferase that was co-transfected into the system (Fig. 2).
As reference, the effect of the well characterized FXR ligand
CDCA (25 lM) versus untreated control was considered 100%,
meaning a signiﬁcant (p <0.001, ANOVA, Bonferroni post-test) acti-
vation of the system. In comparison, at a test concentration of
100 lg/mL, the extracts of the fungus G. lucidum (GL_D and
GL_M) induced FXR by about 150%, which, however, was not sig-
niﬁcantly different from the effect of CDCA. Furthermore, the ethyl
acetate fraction of V. agnus-castus (VAC_EA) stimulated the nuclear
receptor by 110.0%. All other tested extracts induced FXR to a low-
er percentage than the positive control CDCA. Among the pure
compounds, artemisetin (10 lg/mL; 26 lM) and rutamarin
(10 lg/mL; 28 lM) activated FXR signiﬁcantly, but at lower extent
than CDCA. No activation was observed with dihydrocapsaicin
(10 lg/mL; 33 lM).
The data in Figure 2 identify the fruiting bodies of G. lucidum as
promising starting material to scrutinize the active principles
responsible for the observed FXR inducing effect. As the majority
of already known constituents and all the VHs predicted from
Ganoderma belong to the structural class of triterpenoids, respec-
tively steroids, we decided to use a recently developed pharmaco-
phore model42 based on the PDB entry 3bej (co-crystallized with
MFA-1)44 which represents the structural class of steroids as active
constituents (Chart 3). This pharmacophore model (3bej-1-s) con-
sists of three hydrophobic features, two hydrogen bond acceptors
anchoring the ligand with His294 and Thr288, a negatively ioniz-
able feature representing the interaction with Arg331, and 25
exclusion volume spheres as well as a shape constraint for steric
constraints to increase restrictivity (Fig. 3).42 We expected this
model to better represent steroidal compounds and lead to more
triterpenoid hits in the database search. Accordingly, 3bej-1-s
was then used to virtually screen the CHM database.
Due to the high restrictiveness of this structure-based pharma-
cophore model, which focuses on steroid-like compounds, only ten
out of 10,216 structures could map the set features of the model
(hit rate 0.098%). Interestingly, ﬁve of these VHs, namely four gan-
oderic acids and one lucidenic acid (Chart 4), are rare, but charac-
teristic secondary metabolites from G. lucidum. Both types of these
triterpenes are described by an unsaturated lanostane scaffold
with a double bond in position 8 which is in conjugation with
one to two oxo groups in positions 7 and 11. Ganoderic acids pos-
sess a carboxyl group in position 26 distinguishable from lucidenic
acids with a decreased length of the side chain and a carboxyl
group in position 24 (Chart 4).
Intriguingly, the used pharmacophore models, that is, 1osh-1
and 3bej-1-s, have been derived from ligands with unrelated
chemical structures, both are able to ﬁnd steroid-like compounds.
Due to the differing model architecture of 1osh-1 and 3bej-1-s, the
models did not retrieve identical steroidal hits from the CHM data-
base. Anyway, both hit lists suggested lanostane-type triterpenes
as potential FXR ligands. The CHM database used for virtual screen-
ing does not exhaustively cover all currently known TCM
constituents.
As a consequence of the promising FXR-inducing effects deter-
mined for the Ganoderma extracts, and not to neglect further pos-
sibly bioactive compounds, we focused on the evaluation of all
accessible pure constituents from the fruit body of G. lucidum.
Accordingly, 25 previously isolated Ganoderma constituents45,46
were tested for their ability to induce FXR (Chart 5). Except for three
fatty acid derivatives (5–7), they belong to the lanostane-type
triterpenes, which can further be grouped into ergosterol
Table 1
Selected FXR-inducing VHs and respective natural sources predicted by the 1osh-1 pharmacophore model
Capsicum annuum
[fruit]
Ganoderma
lucidum [fruit
body]
Ginkgo biloba
[leave]
Panax ginseng
[root]
Ruta
graveolens
[root; herb]
Vitex agnus-castus
[fruit]
Dihydrocapsaicin Ganoderic acid a Ginnol trans-9,trans-
12-
Linoleic acid
Rotenone Eupatorin
Nordihydrocapsaicin Methyl
ganoderate I
Hydroginkgolinic
acid cis-9,cis-12-
Linoleic acid
Rutamarin 5-Hydroxy-3,6,7,4’-
tetramethoxyﬂavone
Capsanthin
Ganoderic acid Z Cardanol
Isooleic acid
1-Methyl-
2-
undecyl-
4(1H)-
quinolone
Casticin
Ganoderic acid Y cis-9,cis-12-
Linoleic acid 3-
Oxopanaxydol
Artemisetin
Ginkgolic acid
Anacardic acid D
(+)-Catechin-
pentaacetate
Figure 3. 3bej-1-s Pharmacophore model with shape comprising three hydropho-
bic features, two hydrogen bond acceptors anchoring the ligand with His294 and
Thr288, a negatively ionizable feature representing the interaction with Arg331,
and 25 exclusion volume spheres (ligand: MFA-1).
Figure 2. Induction of FXR by DCM (D) andMeOH (M) extracts, one ethyl acetate (EA)
fraction fromdifferent species aswell as threepurecompoundsselected fromtheVH list
of the 1osh-1 pharmacophore model tested in reporter gene assay. Activation of FXR-
driven luciferase reporter in transfected cells was analyzed as described in the
experimental section. The data (mean values ± SEM, n = 4–8) were normalized for
renilla luciferase activity. The results are expressed as the difference in ﬁreﬂy luciferase
activitybetweencontrol andstimulatedcells,normalized to theeffectofpositivecontrol
(CDCA, 25 lM); (n = 7–10; working concentration: extracts and fraction: 100 lg/mL,
pure compounds: 10 lg/mL); (⁄⁄p <0.01, ⁄p <0.05, ANOVA, Bonferroni post-test)
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positions 7/8 and 9/11 (3, 9, 12–14), and lanostanes with a double
bond between position 8/9 (8, 10, 11, 15–25).
The selected compounds were tested in a reporter gene assay
for FXR activation (Fig. 4). The cells were treated with the Ganoder-
ma compounds or the positive control CDCA (25 lM). At a test con-
centration of 10 lM, the effect of seven Ganoderma constituents
reached statistical signiﬁcance, that is, 2, 12, 13, 14, 20 (p <0.001)
and 11, 25 (p <0.01).
A dose-dependent FXR-inducing activity could be conﬁrmed for
ﬁve of these lanostanes, namely for 2, 11, 12, 13, and 14 (Fig. 5)
with EC50 values of 0.85 lM (2), 2.5 lM (13), and 5.0 lM (14). Be-
cause no maximum effect has been reached by compounds 11 and
12 (test concentrations between 0.1 and 50 lM) the half maximal
effective concentrations are estimated above 18.6 lM and 14.0 lM,
respectively. For CDCA, an EC50 of 16.8 lM was determined which
is in agreement with previously published EC50 values for CDCA.3
Thus, the most active lanostanes identiﬁed from G. lucidum, that
is, ergosterol peroxide (2), ganodermanontriol (13), and ganoderiol
F (14) activated FXR at even lower concentrations than CDCA.
In order to obtain an independent evidence of the ability of
the ﬁve lanostane-type triterpenes to activate FXR, we tested
their effects on the expression of a gene known to be downstreamof FXR. CYP7A1 expression is down-regulated by FXR via a well-
characterized molecular mechanism involving SHP and LRH-1,
and is widely used to monitor activity of endogenously expressed
FXR.9 In full agreement with our promoter–reporter data, the ﬁve
tested Ganoderma compounds signiﬁcantly decreased the levels
of CYP7A1 mRNA. The degree of inhibition was similar to that
induced by the positive control CDCA (Fig. 6).
Compounds 2, and 11–14 were further tested for anti-inﬂam-
matory effects. At a test concentration of 5 lM, these FXR-inducing
compounds also prominently inhibited the TNF or LPS induced
expression of IL-8 (Fig. 7A and B) and E-selectin (Fig. 7C and D)
in human endothelial cells. These effects are comparable with
the NFjB pathway inhibitor BAY-11-7085 at equimolar concentra-
tions (5 lM). The observed FXR induction indicates a possible
involvement of this nuclear receptor in the mechanism of the
inﬂammatory regulation by these compounds.
In an attempt to identify themost appropriatemodel for triterpe-
noid FXR modulators, 13 pharmacophore models, generated and
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Chart 4. VHs resulting from the virtual screening of the 3bej-1-s pharmacophore model: 5 of 10 VHs are constituents from G. lucidum (bold names).
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LigandScout.47 These models, covering diverse FXR ligands with
different bindingmodes, represent helpful tools for pharmacophore
proﬁling of the investigated 25 Ganoderma constituents (Table 2).
The proﬁling results, which were performed in a rigid ﬁtting
mode, show that the highest number of Ganoderma constituents
can be identiﬁed by virtual screening with the 3bej-2 model, as
the underlying PDB entry 3bej comprises a steroidal ligand. In
comparison to the 3bej-1s model (Fig. 3), the chemical features
on the side chain have been deleted and the ionic interaction with
Arg331 is represented by a hydrogen bond acceptor instead of a
negatively ionizable feature (Fig. 8). However, despite the signiﬁ-
cant generalization resulting from this modiﬁcation, 3bej-2 still
was not able to ﬁnd all FXR-active compounds, which might be ex-
plained by the applied rigid ﬁtting mode and the deﬁned confor-
mation of the structures. In ﬂexible ﬁtting mode all FXR-active
compounds from G. lucidum except for compound 2 were found.This can be explained by the lack of a hydrogen bond accepting
group in compound 2 that could map the feature towards
His447, near position 17. Remarkably, this His447 interaction is
only present in the 3bej-based models. Obviously this interaction
is not crucial for FXR agonism. At the same time, 3bej-2 has been
shown to be the best predictive model for the triperpene com-
pounds. The model could therefore be optimized in terms of mak-
ing the hydrogen bond acceptor towards His447 an optional
feature, which, however, would loosen signiﬁcantly the model’s
restrictiveness in the virtual screening ﬁltering experiment. As
negative control for the application of the 3bej-2 model, the FXR-
inactive group of fatty acid derivatives, that is, 5, 6, and 7 was nei-
ther found by a rigid nor by a ﬂexible screening mode.
In order to get deeper structural insights into triterpenoid-med-
iated FXR activation, the most active compounds 2 and 13 were
docked into the FXR ligand binding domain. The PDB entry 3bej44
was selected as 3D representation of the FXR binding pocket
HO
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HO
O
O
ergosterol peroxide (2)
HO
O
O
(22E,24R)-5α,8α-epidioxyergosta-
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Chart 5. Chemical structures of tested G. lucidum substances.
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best reﬂect the FXR receptor conformation when bound to a triter-
pene ligand (Fig. 8). Among the predicted binding poses, two dis-
tinct binding orientations of the steroid ring were observed: The
positioning of 2 was similar to the experimentally determined
binding mode of MFA-1 in 3bej. In contrast, a ﬂipped orientation
was observed for compound 13. Interestingly, this binding mode
corresponds to the 6-ECDCA orientation within the rat FXR binding
site determined by X-ray crystallography (PDB entry 1osv48) and
was also in line with SAR studies on bile alcohols as FXR ligands
by Iguchi et al.49 In both docked ligand orientations, interactions
with Arg331 via hydrogen bonds were observed (Fig. 9). All other
contacts to the non-polar binding pocket were established via
hydrophobic groups.
3. Conclusions
For the target-oriented selection of natural products and their
constituents interacting with FXR we used a combination of phar-
macophore-based virtual screening and experimental validation of
multi-component mixtures. Accordingly, the heuristic assumptionof FXR-inducing lanostane-type triterpenes from G. lucidum to-
gether with the positively tested extracts of this TCM mushroom
prompted us to investigate 25 Ganoderma constituents. Five lanos-
tanes were identiﬁed as distinct FXR-inducing natural compounds.
An FXR agonistic activity of these compounds was conﬁrmed using
two independent approaches, that is, a promoter–reporter study
and analysis of the mRNA levels of the FXR-regulated gene CYP7A1.
Additionally, the inhibition of TNF or LPS induced expression of
IL-8 and E-selectin in human endothelial cells proposes these
compounds as constituents of G. lucidum accountable for its
anti-inﬂammatory effect. These mechanisms may involve the
regulation of the nuclear receptor FXR by these compounds.
The applied in silico approach provided us with a targeted selec-
tion of promising natural starting material by correctly predicting
the novel FXR-inducing chemical class of lanostane-type triter-
penes. Investigation of the putative binding mode by molecular
docking studies of the most active compounds ergosterol peroxide
(2) and ganodermanontriol (13) enabled insight into the binding
mode, which revealed crucial hydrogen bond interactions between
the contemplated structure and Arg331 of the nuclear receptor
backbone.
R1 R2
R3
R4 R6
R5
R1 R2 R3 R4 R5 R6
ganoderic acid DM (8) O O H H H COOH
ganoderon B (10) OH O H H H OH
lucidumol A (11) O O H H H
OH
OH
lucidenic acid A (15) O OH O H O COOH
ganoderic acid D (16) O OH O H O
COOHO
ganoderic acid F (17) O O O OO O COOHO
ganoderenic acid D (18) O OH O H O
COOHO
ganoderic acid J (19) O O O H OH
COOHO
ganoderic acid B (20) OH OH O H O
COOHO
ganoderic acid A (21) O OH O H OH
COOHO
12β-hydroxy-3,7,11,15,23-
pentaoxo-5α-lanost-8-en-
26-oic acid (22)
O O O O O
COOHO
methyl ganoderate H (23) OH O O OO O COOCH3O
ganoderic acid H (24) OH O O OO O COOHO
ganoderic acid AM1 (25) OH O O H O
COOHO
Chart 5. (continued)
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4.1. Virtual Chinese Herbal Medicine (CHM) database
The molecular 3D database CHM used in this study has been
generated previously.43 It comprises 10,216 compounds, which
are related to natural products used in traditional Chinese medi-
cine. The 3D structures of the compounds were built and conse-
quently energetically minimized using the structure editor of
Catalyst (www.accelrys.com). The ConFirm algorithm was applied
to create conformational models for the compounds using the
following settings: maximum number of conformers = 100,generation type = fast quality, and energy range = 20 kcal/mol
above the calculated lowest energy conformation.43
4.2. Model generation for a pharmacophore-based virtual
screening
The two ligand-receptor complexes used for pharmacophore
creation are accessible via the PDB with the accession codes 1osh
and 3bej,44 respectively. Models based on these PDB entries were
generated using LigandScout software.47 The resulting models
were exported into DiscoveryStudio (www.accelrys.com) for opti-
mization and virtual screening. For each model, one version
Figure 5. Dose-dependent activation of FXR reporter by selected G. lucidum constituents. Effects of indicated concentrations of compounds 2, 11, 12, 13 and 14 on activity of
FXR-driven luciferase reporter were determined as described in Figure 2. The data were normalized to expression of renilla luciferase (mean values ± SEM, n = 4–8). For 11
and 12 the exact EC50 values could not be determined since the induction did not reach saturation at maximal concentrations used in this experiment (50 lM). Very similar
data were obtained in an independent experiment.
Figure 6. Expression of CYP7A1 mRNA. HepG2 cells treated with 2, 12, 13 and 14
(50 lM) for 6 h in DMEM containing 10% FCS; data expressed as fold of control cells
treated with medium/0.1% DMSO; (⁄p <0.05, ⁄⁄p <0.01).
Figure 4. Induction of FXR-dependent transcription by G. lucidum constituents (compounds 1–25, 10 lM each). The data (mean values ± SEM, n = 4–8) were normalized for
renilla luciferase activity. The results are expressed as the difference in ﬁreﬂy luciferase activity between control and stimulated cells, normalized to the effect of positive
control (CDCA, 25 lM); (⁄⁄⁄p <0.001, ⁄⁄p <0.01, +++p <0.001, ANOVA, Bonferroni post-test)
U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791 6787containing a shape (-s) restriction was generated using the bound
ligand in the respective PDB complex entry.
4.3. Virtual screening of the Ganoderma compounds
The structures of all available isolated constituents from G. luci-
dum (1–25) were generated using ChemBioDraw Ultra 11.0. Allcompounds were exported as sd-ﬁles and submitted to conforma-
tional analysis using Discovery Studio 2.5 and the ‘BEST’ option. For
each molecule, a maximum of 255 conformers within an energy
range of 20 kcal/mol above the calculated energy minimumwas al-
lowed. The parallel mapping of the 25 compounds into FXR agonist
pharmacophore models was performed using the ‘Ligand Proﬁler’
protocol of Discovery Studio with the ‘BEST’ ﬁtting algorithm and
a minimum inter-feature distance of 0.00001. All other parameters
were kept as default.
4.4. Natural material and isolated pure compounds
The dried fruiting bodies ofG. lucidum used for the preparation of
extracts were purchased in Beijing, China. The quality was checked
according to the monograph língzhı¯ of the Chinese Pharmacopoeia.
The fruit powder of Capsicum annuum, the dried leaves of G. biloba,
the dried herb material of R. graveolens, and the dried fruits of
V. agnus-castus were obtained from ‘Mag. Kottas–Heilkräuter’,
Eitnergasse 8, 1230 Vienna, Austria. The dried roots of R. graveolens
were supplied by ‘Johann Strillinger–Gartenbau’, Eiberg 8, 6306 Söll,
Austria. The dried roots of P. ginseng were purchased from
‘Mag. Stöger–Plantasia’, Heinrich-Handel-Mazzetti-Platz, 5110
Oberndorf, Austria.
Voucher specimens (JR-20080605-A1, JR-20080429-A4,
JR-20080429-A3, JR-20080429-A1, JR-20080429-A2, JR-20051
Figure 7. Anti-inﬂammatory effect of FXR inducing compounds from G. lucidum was determined in HUVEC as described in experimental section. The effect of compounds
(5 lM) on TNF (100 ng/mL) or LPS (300 ng/mL) induced IL-8 (A, B) and E-Selectin (C, D) is expressed as fold induction of the respective mRNA expression in comparison with
the untreated control; (⁄⁄⁄p <0.001, ANOVA, Bonferroni post-test).
Table 2
Pharmacophore proﬁling results of all models used in this study against the 25 tested Ganoderma constituents (+, VHs; , virtual non-hits; Ganoderma compounds with
experimentally determined FXR-inducing activity at 10 lM are highlighted in gray)
6788 U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791009-A1, JR-20091203-D1) are deposited in the Herbarium of the
Institute of Pharmacy/Pharmacognosy, University of Innsbruck,
Austria.
Dichloromethane (DCM) and methanolic (MeOH) extracts were
produced from the six selected natural materials. In a preliminary
step 1 g of each drug was chopped and subsequently extracted for
15 min with 10 mL DCM in an ultrasonic bath. After centrifugationthe supernatant was evaporated under reduced pressure and the
acquired DCM crude extract was collected. After drying of the
remaining drug material a methanolic crude extract was then ob-
tained by the same procedure as described above.
For the preparation of the enriched ethyl acetate (EA) fraction of
V. agnus-castus, 200 g ground fruits were subjected to a Soxhlet
extraction with 70% ethanol as a solvent. After four days the
Figure 8. Best ﬁtting FXR pharmacophore model (3bej-2) for investigated Ganoderma constituents. Crucial interactions of the ligand (MFA-1) with Arg331 and His447 are
highlighted in ball-and-stick style.
Figure 9. Predicted interactions of 2 and 13 with the Arg331 residue of the FXR protein backbone via hydrogen bonds.
U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791 6789obtained ethanolic extract (28.43 g) was suspended in water and
subsequently partitioned between n-hexane (4  200 mL) and EA
(3  200 mL). The EA fraction was investigated by LC–MS and
proved to be enriched with virtually predicted ﬂavonoids.
Extraction and isolation procedure of the Ganoderma constitu-
ents 1–25 as well as their physico-chemical properties were
described previously.45,46,50–53 The purity of these compounds
was determined by HPLC and NMR to be P 98%.
Dihydrocapsaicin (declared purity approx. 90%) was purchased
from Sigma–Aldrich (St. Louis, MO).
4.5. Cell culture, plasmids, and reagents
Human embryonic kidney-293 cells (HEK-293) from American
Type Culture Collection (Manassas, VA, USA) were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) (Sigma, St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS), penicillin/
streptomycin, and 1% L-glutamine. TERT technology (hTERT)
immortalized human umbilical vein cells (HUVECtert)54 were cul-
tured in M199 Medium (Sigma–Aldrich, St. Louis, MO) supple-
mented with 20% FBS, endothelial cell growth supplement
(Technoclone, Austria) and antibiotics. The luciferase reporter
plasmid (ECRE)5TK-Luc, the expression vector for mouse FXR, the
expression vector for mouse RXR were kindly provided by Profes-sor Glass CK (UCSD, La Jolla, CA). The vector pSV40-renillaLuc
was obtained from Promega (Madison, WI, USA), the pcDNA3.1
from Invitrogen (Carlsbad, CA, USA). DMSO, CDCA and LPS (Esche-
richia coli 055:B5) were purchased from Sigma–Aldrich (St. Louis,
MO), human recombinant TNFa was obtained from Peprotech
(Rocky Hill, NJ).
4.6. Reporter gene assay for FXR activation
Activation of FXR was tested in HEK-293 cells seeded in 48 well
plates (NUNC) and transiently transfected with the elements of the
FXR reporter assay system (total DNA 0.3 ng/well). The ﬁreﬂy lucif-
erase reporter containing quintuple RXR:FXR binding site and the
respective expression plasmids for full length murine FXR and
RXRa were introduced by transient transfection performed with
the calcium phosphate technique. For monitoring transfection efﬁ-
ciency pSV40-renillaLuc was cotransfected. To normalize the
amount of DNA transfected, pcDNA3.1 vector was added where
appropriate. Cells were stimulated for 18 h with vehicle (DMSO)
or with ligands at concentrations as indicated. Luciferase activity
was determined from the cell lysates using Dual-Luciferase Kit
(Promega, Madison, WI, USA), measured with Victor2 multilabel
counter (Wallac, Finland). The ﬁreﬂy luciferase values were
normalized with the renilla luciferase value measured for the
6790 U. Grienke et al. / Bioorg. Med. Chem. 19 (2011) 6779–6791respective sample (relative luciferase units). FXR induction was
determined as measurement of three independent experiments
performed in quadruplicates and expressed as percent induction
(mean values ± SEM) compared with the FXR ligand CDCA used
as a reference in each respective experiment. Statistical signiﬁ-
cance of FXR induction was assessed by ANOVA-multiple compar-
ison with Bonferroni post-test, whereby p values of less than 0.05
were regarded as statistically signiﬁcant. The EC50 values were cal-
culated by non-linear regression analysis using the equation for
the sigmoidal dose response of GraphPad Prism 4.0 (GraphPad
Software Inc., La Jolla, CA).
4.7. Inhibition of expression of inﬂammatorymediators and cell
adhesion molecules
Monolayers of subconﬂuent quiescent HUVECtert cells were
pre-treated for 10 min with the plant material or inhibitor as indi-
cated, followed by stimulation with 100 ng/mL of TNFa (Pepro-
Tech, Rocky Hill, NJ) or 300 ng/mL of LPS (Sigma–Aldrich, St.
Louis, MO) for 30 min or 4 h, respectively. RNA was extracted from
the cells using QIAzol lysis reagent (Qiagen, Hilden, Germany),
900 ng of RNA was reverse transcribed with MulV-RT using Oligo
d(T) primers (Applied Biosystems, Carlsbad, CA). Relative expres-
sion of the genes of interest was determined by Q-PCR (Roche,
Basel, Switzerland). Primers were designed with PRIMER3 software
from the Whitehead Institute for Biomedical Research (Cambridge,
MA) using the reference mRNA sequences of respective genes from
the GeneBank (www.ncbi.nlm.nih.gov). For inteleukin-8 primers
50-ctcttggcagccttcctgatt-30(forward) and 50-tatgcactgacatctaagttct
ttagca-30(reverse), for E-selectin 50-ggtttggtgaggtctgctc-30(forward)
and 50-tgatctgtcccggaactgc-30(reverse) were used. Relative quanti-
ﬁcation of the investigated genes was calculated by normalization
to a housekeeping gene b2-microglobulin using the mathematical
model by Pfafﬂ,55 and presented as fold variation over the control.
4.8. Analysis of expression of FXR downstream genes by qPCR
HepG2 cells were grown in 24-well dishes (NUNC) in DMEM
supplemented with antibiotics (100 U/mL penicillin, 100 lg/mL
streptomycin, 25 lg/mL amphotericin B), 1% glutamine and 10%
FBS. The cells were stimulated in the same medium with the ana-
lyzed compounds or positive control (chenodeoxycholic acid,
CDCA) dissolved in DMSO (ﬁnal concentration 0.1%) at a concentra-
tion of 50 lM for 6 h. The incubation was terminated and RNA was
isolated using TriFast reagent (PeqLab, Erlangen, Germany). A Gene-
Amp RNA-PCR kit and oligo d(T)16 primers (Applied Biosystems,
Foster City, CA) were used for cDNA synthesis from 900 ng of total
RNA. Quantitative real-time PCR (qPCR) was performed using the
Step One Plus (Applied Biosystems), FastStart SYBR Green Master
Mix (Roche Diagnostics, Indianapolis, IN), and speciﬁc primers for
ampliﬁcation of CYP7A1 (Qiagen, Venlo, The Netherlands). CYP7A1
expression was normalized to the expression levels of b2-micro-
globulin using primers obtained from the same company.
4.9. Computational docking
Computational docking experiments were performed using
GOLD 3.1 (www.ccdc.cam.ac.uk/products/life_sciences/gold/) with
default settings. Protein and ligand preparations for docking were
performed within GOLD.
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